Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the novel non-covalent BTK inhibitor, pirtobrutinib, and its efficacy across B-cell malignancies, particularly in diseases like mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). He highlights its role as a bridge to CAR T-cell therapy, with promising early data showing potential improvements in the quality of T-cells. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Pirtobrutinib as a bridge to CAR-T therapy in B-cell malignancies
Теги
Institution: Medical College of WisconsinEvent: SOHO 2024Format: InterviewSubject: Chronic Lymphocytic LeukemiaSubject: LeukemiaField: TreatmentMedicines: PirtobrutinibMedicines: IbrutinibMedicines: ZanubrutinibSubject: Mantle Cell LymphomaSubject: LymphomaSubject: Non-Hodgkin LymphomaField: CAR-T & Cellular TherapyField: Immuno-OncologyField: Gene TherapyMedicines: CAR-TMedicines: AcalabrutinibBTK inhibitorsSpeaker: Nirav Niranjan Shah
